172 related articles for article (PubMed ID: 37240355)
1. Novel Allosteric Effectors Targeting Human Transcription Factor TEAD.
Ibrahim MT; Verkhivker GM; Misra J; Tao P
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240355
[TBL] [Abstract][Full Text] [Related]
2. Small-Molecule Covalent Modification of Conserved Cysteine Leads to Allosteric Inhibition of the TEAD⋅Yap Protein-Protein Interaction.
Bum-Erdene K; Zhou D; Gonzalez-Gutierrez G; Ghozayel MK; Si Y; Xu D; Shannon HE; Bailey BJ; Corson TW; Pollok KE; Wells CD; Meroueh SO
Cell Chem Biol; 2019 Mar; 26(3):378-389.e13. PubMed ID: 30581134
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Design of Y-Shaped Covalent TEAD Inhibitors.
Lu W; Fan M; Ji W; Tse J; You I; Ficarro SB; Tavares I; Che J; Kim AY; Zhu X; Boghossian A; Rees MG; Ronan MM; Roth JA; Hinshaw SM; Nabet B; Corsello SM; Kwiatkowski N; Marto JA; Zhang T; Gray NS
J Med Chem; 2023 Apr; 66(7):4617-4632. PubMed ID: 36946421
[TBL] [Abstract][Full Text] [Related]
4. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
[TBL] [Abstract][Full Text] [Related]
5. A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer.
Zhu C; Li L; Zhang Z; Bi M; Wang H; Su W; Hernandez K; Liu P; Chen J; Chen M; Huang TH; Chen L; Liu Z
Mol Cell; 2019 Aug; 75(4):791-806.e8. PubMed ID: 31303470
[TBL] [Abstract][Full Text] [Related]
6. The interaction of TEA domain transcription factor 4 (TEAD4) and Yes-associated protein 1 (YAP1) promoted the malignant process mediated by serum/glucocorticoid regulated kinase 1 (SGK1).
He S; Zhang H; Xiao Z; Bhushan S; Gao K; Wang W
Bioengineered; 2021 Dec; 12(1):601-614. PubMed ID: 33517828
[TBL] [Abstract][Full Text] [Related]
7. Leveraging the Fragment Molecular Orbital and MM-GBSA Methods in Virtual Screening for the Discovery of Novel Non-Covalent Inhibitors Targeting the TEAD Lipid Binding Pocket.
Kim J; Jin H; Kim J; Cho SY; Moon S; Wang J; Mao J; No KT
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791396
[TBL] [Abstract][Full Text] [Related]
8. Structural and ligand-binding analysis of the YAP-binding domain of transcription factor TEAD4.
Li Y; Liu S; Ng EY; Li R; Poulsen A; Hill J; Pobbati AV; Hung AW; Hong W; Keller TH; Kang C
Biochem J; 2018 Jun; 475(12):2043-2055. PubMed ID: 29760238
[TBL] [Abstract][Full Text] [Related]
9. Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma.
Saunders JT; Holmes B; Benavides-Serrato A; Kumar S; Nishimura RN; Gera J
J Neurooncol; 2021 Apr; 152(2):217-231. PubMed ID: 33511508
[TBL] [Abstract][Full Text] [Related]
10. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.
Zhou Z; Hu T; Xu Z; Lin Z; Zhang Z; Feng T; Zhu L; Rong Y; Shen H; Luk JM; Zhang X; Qin N
FASEB J; 2015 Feb; 29(2):724-32. PubMed ID: 25384421
[TBL] [Abstract][Full Text] [Related]
11. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
12. RBFOX2-regulated TEAD1 alternative splicing plays a pivotal role in Hippo-YAP signaling.
Choi S; Lee HS; Cho N; Kim I; Cheon S; Park C; Kim EM; Kim W; Kim KK
Nucleic Acids Res; 2022 Aug; 50(15):8658-8673. PubMed ID: 35699208
[TBL] [Abstract][Full Text] [Related]
13. OTUD6A orchestrates complex modulation of TEAD4-mediated transcriptional programs.
Kim HJ; Choi Y; Lee Y; Hwangbo M; Kim J
FEBS Lett; 2024 May; 598(9):1045-1060. PubMed ID: 38594215
[TBL] [Abstract][Full Text] [Related]
14. Dissection of the interaction between the intrinsically disordered YAP protein and the transcription factor TEAD.
Mesrouze Y; Bokhovchuk F; Meyerhofer M; Fontana P; Zimmermann C; Martin T; Delaunay C; Erdmann D; Schmelzle T; Chène P
Elife; 2017 Apr; 6():. PubMed ID: 28430104
[TBL] [Abstract][Full Text] [Related]
15. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling.
Ota M; Sasaki H
Development; 2008 Dec; 135(24):4059-69. PubMed ID: 19004856
[TBL] [Abstract][Full Text] [Related]
16. Identification of a derivative of the alkaloid emetine as an inhibitor of the YAP-TEAD interaction and its potential as an anticancer agent.
Sekine S; Takase S; Hayase R; Noritsugu K; Maemoto Y; Ichikawa Y; Ogawa K; Kondoh Y; Osada H; Yoshida M; Ito A
Biosci Biotechnol Biochem; 2023 Apr; 87(5):501-510. PubMed ID: 36809780
[TBL] [Abstract][Full Text] [Related]
17. Chloroacetamide fragment library screening identifies new scaffolds for covalent inhibition of the TEAD·YAP1 interaction.
Bum-Erdene K; Ghozayel MK; Zhang MJ; Gonzalez-Gutierrez G; Meroueh SO
RSC Med Chem; 2023 Sep; 14(9):1803-1816. PubMed ID: 37731696
[TBL] [Abstract][Full Text] [Related]
18. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain.
Lamar JM; Stern P; Liu H; Schindler JW; Jiang ZG; Hynes RO
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):E2441-50. PubMed ID: 22891335
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode.
Hu L; Sun Y; Liu S; Erb H; Singh A; Mao J; Luo X; Wu X
Elife; 2022 Nov; 11():. PubMed ID: 36398861
[TBL] [Abstract][Full Text] [Related]
20. CK2-induced cooperation of HHEX with the YAP-TEAD4 complex promotes colorectal tumorigenesis.
Guo Y; Zhu Z; Huang Z; Cui L; Yu W; Hong W; Zhou Z; Du P; Liu CY
Nat Commun; 2022 Aug; 13(1):4995. PubMed ID: 36008411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
